dc.contributor.author
Bonzheim, Irina
dc.contributor.author
Sander, Philip
dc.contributor.author
Salmerón Villalobos, Julia
dc.contributor.author
Süsskind, Daniela
dc.contributor.author
Szurman, Peter
dc.contributor.author
Gekeler, Florian
dc.contributor.author
Spitzer, Martin S.
dc.contributor.author
Steinhilber, Julia
dc.contributor.author
Kohler, Esther
dc.contributor.author
Büssgen, Melanie
dc.contributor.author
Schittenhelm, Jens
dc.contributor.author
Salaverria Frigola, Itziar
dc.contributor.author
Campo Güerri, Elias
dc.contributor.author
Coupland, Sarah E.
dc.contributor.author
Quintanilla Martinez, Leticia
dc.contributor.author
Fend, Falko
dc.date.issued
2023-06-16T11:45:39Z
dc.date.issued
2023-06-16T11:45:39Z
dc.date.issued
2022-03-07
dc.date.issued
2023-06-08T09:29:11Z
dc.identifier
https://hdl.handle.net/2445/199342
dc.description.abstract
Vitreoretinal lymphoma (VRL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) considered a variant of primary central nervous system lymphoma (PCNSL). Diagnosis of VRL requires examination of vitreous fluid, but cytologic differentiation from uveitis remains difficult. Due to its rarity and difficulty in obtaining diagnostic material, little is known about the genetic profile of VRL. The aim of our study was to investigate the mutational profile of a large series of primary and secondary VRL. Targeted next generation sequencing using a custom panel containing the most frequent mutations in PCNSL was performed on 34 vitrectomy samples of 31 patients with VRL and negative controls with uveitis. In a subset of cases, genome-wide copy number alterations (CNA) were assessed using the Oncoscan platform. Mutations in MYD88 (74%), PIM1 (71%), CD79B (55%), IGLL5 (52%), TBL1XR1 (48%), ETV6 (45%) and 9p21/CDKN2A deletions (85%) were the most common alterations, with similar frequencies in primary (15), synchronous (3) or secondary (13) VRL. This mutational spectrum is similar to MYD88mut/CD79Bmut (MCD or cluster 5) DLBCL with activation of Toll-like and B-cell receptor pathways and CDKN2A loss, confirming their close relationship. Oncoscan analysis demonstrated a high number of CNAs (mean 18.6/case). Negative controls lacked mutations or CNAs. Using cell free DNA of vitreous fluid supernatant, mutations present in cellular DNA were reliably detected in all examined cases. Mutational analysis is a highly sensitive and specific tool for the diagnosis of VRL and can also be applied successfully to cell free DNA derived from the vitreous.Copyright © 2021 American Society of Hematology.
dc.format
application/pdf
dc.publisher
American Society of Hematology (ASH)
dc.relation
Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2021004212
dc.relation
Blood Advances, 2022, vol. 6, num. 5, p. 1598-1607
dc.relation
https://doi.org/10.1182/bloodadvances.2021004212
dc.rights
cc by-nc-nd (c) Bonzheim, Irina et al, 2022
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject
Malalties del sistema limfàtic
dc.subject
Biologia molecular
dc.subject
Lymphatic diseases
dc.subject
Molecular biology
dc.title
The molecular hallmarks of primary and secondary vitreoretinal lymphoma
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion